These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28767185)

  • 1. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.
    Cummings J
    Clin Transl Sci; 2018 Mar; 11(2):147-152. PubMed ID: 28767185
    [No Abstract]   [Full Text] [Related]  

  • 2. Alzheimer's disease: future drug development and the blood-brain barrier.
    Pardridge WM
    Expert Opin Investig Drugs; 2019 Jul; 28(7):569-572. PubMed ID: 31155971
    [No Abstract]   [Full Text] [Related]  

  • 3. Measuring disease modification in Alzheimer's disease.
    Cummings JL
    CNS Spectr; 2007 Jan; 12(1 Suppl 1):11-4. PubMed ID: 17712916
    [No Abstract]   [Full Text] [Related]  

  • 4. Pomegranate's Neuroprotective Effects against Alzheimer's Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites.
    Yuan T; Ma H; Liu W; Niesen DB; Shah N; Crews R; Rose KN; Vattem DA; Seeram NP
    ACS Chem Neurosci; 2016 Jan; 7(1):26-33. PubMed ID: 26559394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Be open about drug failures to speed up research.
    Alteri E; Guizzaro L
    Nature; 2018 Nov; 563(7731):317-319. PubMed ID: 30425369
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
    Bullock R; Passmore P; Wilkinson D; Howard R; Jones R
    BMJ; 2000 Feb; 320(7233):511-2. PubMed ID: 10678874
    [No Abstract]   [Full Text] [Related]  

  • 7. Does statin use decrease the amount of Alzheimer disease pathology in the brain?
    Silbert LC
    Neurology; 2007 Aug; 69(9):E8-11. PubMed ID: 17724280
    [No Abstract]   [Full Text] [Related]  

  • 8. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.
    Qosa H; Batarseh YS; Mohyeldin MM; El Sayed KA; Keller JN; Kaddoumi A
    ACS Chem Neurosci; 2015 Nov; 6(11):1849-59. PubMed ID: 26348065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease.
    Reddy PH; Manczak M; Yin X; Grady MC; Mitchell A; Tonk S; Kuruva CS; Bhatti JS; Kandimalla R; Vijayan M; Kumar S; Wang R; Pradeepkiran JA; Ogunmokun G; Thamarai K; Quesada K; Boles A; Reddy AP
    J Alzheimers Dis; 2018; 61(3):843-866. PubMed ID: 29332042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mounting a defence against Alzheimer's disease.
    Ross M
    CMAJ; 1999 Mar; 160(6):773. PubMed ID: 10189410
    [No Abstract]   [Full Text] [Related]  

  • 11. Resveratrol, pterostilbene, and dementia.
    Lange KW; Li S
    Biofactors; 2018 Jan; 44(1):83-90. PubMed ID: 29168580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine as a neuroprotective adenosine receptor antagonist.
    Dall'Igna OP; Souza DO; Lara DR
    Ann Pharmacother; 2004 Apr; 38(4):717-8. PubMed ID: 14982979
    [No Abstract]   [Full Text] [Related]  

  • 13. Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice.
    Batarseh YS; Bharate SS; Kumar V; Kumar A; Vishwakarma RA; Bharate SB; Kaddoumi A
    ACS Chem Neurosci; 2017 Aug; 8(8):1756-1766. PubMed ID: 28471166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection: promise and pitfalls in anti-inflammatory treatment of Alzheimer's disease.
    Memo M; Blandini F; Nappi G; Spano P
    Funct Neurol; 2002; 17(4):175-6. PubMed ID: 12675259
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental therapeutics of neurodegenerative disorders: unmet needs.
    Shoulson I
    Science; 1998 Nov; 282(5391):1072-4. PubMed ID: 9804537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.
    Plangár I; Zádori D; Klivényi P; Toldi J; Vécsei L
    J Alzheimers Dis; 2011; 24 Suppl 2():199-209. PubMed ID: 21441658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginkgo biloba prevention trials: more than an ounce of prevention learned.
    Kaye J
    Arch Neurol; 2009 May; 66(5):652-4. PubMed ID: 19433666
    [No Abstract]   [Full Text] [Related]  

  • 18. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism.
    Zhang J; Cao Q; Li S; Lu X; Zhao Y; Guan JS; Chen JC; Wu Q; Chen GQ
    Biomaterials; 2013 Oct; 34(30):7552-62. PubMed ID: 23849878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: The right drug, the right time.
    Golde TE; DeKosky ST; Galasko D
    Science; 2018 Dec; 362(6420):1250-1251. PubMed ID: 30545877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.